Search the Newsreel

Evommune Reports Second Quarter 2026 Financial Results and Provides Business Highlights

Evommune, Inc. announced its second quarter 2026 financial results, highlighting key advancements in its clinical pipeline. The company expects to report top-line data for its EVO756 atopic dermatitis (AD) Phase 2b trial in September 2026 and has initiated a Phase 2b trial for EVO756 …

Evotec SE (EVO) Aktuelle Aktien-News

Evogene Ltd (EVGN) Earnings Forecast: Future EPS & Revenue Growth Estimates

Evogene Ltd (EVGN) has an earnings forecast score of 8.00, placing it 171st out of 387 in its industry. Analysts have set an average price target of $2.50, with a consensus "Buy" rating based on one analyst. The company's expected revenue for the next …

Gevo, Inc. (GEVO) CFO sells 18,223 shares in Rule 10b5-1 plan trade

Gevo, Inc.'s CFO, Agiri Oluwagbemileke Yusuf, sold 18,223 shares of common stock on August 6, 2026, at a weighted average price of $1.5384 per share through a pre-arranged Rule 10b5-1 trading plan. After the sale, he directly beneficially owns 472,893 shares and indirectly holds …

Gevo Inc Earnings Call: Growth, Credits and Risks

Gevo Inc. reported its Q2 2026 earnings, showcasing revenue growth, surging gross profits, and a doubled adjusted EBITDA outlook for 2026. The company's strategy heavily relies on carbon credits, tax incentives, and project financing, which also introduce execution risks despite strong operational momentum. Key …

Northland Securities Maintains Gevo Inc(GEVO.US) With Buy Rating, Maintains Target Price $3.75

Northland Securities has reiterated its Buy rating on Gevo Inc (GEVO.US) and maintained its target price of $3.75. This continued positive outlook from the firm suggests confidence in Gevo's future performance.

Evogene Ltd. (EVGN) investor group boosts ownership to 15.98%

An investor group linked to L.I.A. Pure Capital Ltd., Invest Pro Shukai Hon Ltd., Kfir Silberman, and Ron Yair Peled has increased its stake in Evogene Ltd. (EVGN) to approximately 15.98% of the outstanding ordinary shares. This increase follows open-market purchases of 216,300 American …

'We're excited and ready to go': Fast-growing Revolution Medicines preps potential launch of blockbuster pancreatic cancer drug

Revolution Medicines is preparing for the potential launch of its pancreatic cancer drug, daraxonrasib. The Redwood City-based company, led by CEO Mark Goldsmith, boasts a substantial financial reserve of $3.9 billion in cash and equivalents, positioning it strongly among mid-size biotechs for this significant …

Evotec and Odyssey Forge AI-Powered Drug Discovery Pact Targeting Autoimmune Diseases

Evotec SE and Odyssey Therapeutics Inc. have announced a strategic AI-enabled R&D collaboration aimed at discovering new small molecule treatments for autoimmune and inflammatory diseases. The partnership combines Odyssey's disease biology expertise with Evotec's integrated discovery platform, advanced screening technologies, and proprietary compound libraries. …

Análise e Previsão das Ações da Devon Energy Corp (DVN)

RVLV Q2 Beat Masks Tariff Boost as 2026 Investment Spending Rises

Revolve Group, Inc. RVLV beat second-quarter earnings expectations as sales growth stayed broad and underlying merchandising economics improved. Yet tariff refunds amplified reported profitability, making the quality of the margin gain an important part of the quarter. Management is also spending more on long-term …

Is RVLV Stock a Buy as Growth Accelerates but Valuation Stays Rich?

Revolve Group, Inc. RVLV is showing better operating momentum, with faster demand, customer growth and broad-based gains across its businesses. The question is whether that improvement is enough to justify a premium valuation. Investors also have to weigh elevated spending, inventory growth and tariff-related …

RVLV Surges 33.1% in Three Months: Can Its Momentum Keep Building?

Revolve Group, Inc. RVLV shares have climbed 33.1% over the past three months, bringing the durability of the rally into focus. The move has coincided with faster sales growth, customer gains and better underlying merchandise margins. The operating backdrop is improving, but the stock …

Evolution Global Acquisition Ord Shs Class A (EVOX) Stock News Today

Evolution Global Acquisition Ord Shs Class A (EVOX) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Evolution Global Acquisition Ord Shs Class A (EVOX), detailing future EPS and revenue growth estimates. It includes a stock overview with market capitalization and current stock price, along with a peer comparison. The forecast also covers expected …

Revolution Medicines, Inc. (RVMD) interactive stock chart

Evommune, Inc. 2Q 2026: Revenue $0 Net loss $53.9M — 10-Q Summary

Evommune, Inc. reported no revenue and a net loss of $53.9 million for the second quarter of 2026, an increase from a $28.1 million net loss in the prior year. The company ceased development of EVO756 for chronic spontaneous urticaria but continues trials for …

Evommune Inc (EVMN) Stock News Today

This article provides current stock information for Evommune Inc (EVMN), including its market performance, market cap, and a note that more news will be coming soon. As of August 7th, the stock closed at 14.080 USD, up 5.49%. The platform offers news, analysis, financials, …

Evolus, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:EOLS) 2026-08-06

This article announces that Evolus, Inc. (EOLS) published its Q2 2026 earnings call presentation on August 6, 2026. The company reported Q2 EPS of -$0.02, beating estimates by $0.02, and revenue of $84.08 million, a 21.18% year-over-year increase, beating estimates by $2.54 million. The …

Revolve Group, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Evommune Inc (EVMN) Earnings Forecast: Future EPS & Revenue Growth Estimates

Devon Energy Corp (DVN) Gewinnprognose: Zukünftige EPS & Umsatzwachstumsprognosen

Das prognostizieren Analysten für die Evonik Industries AG (ETR:EVK) nach der Veröffentlichung der Ergebnisse für das zweite Quartal

Evolus (EOLS) Stock Jumps On Margin Turn And EBITDA Momentum

GEVO Q2 Deep Dive: Carbon Strategy and North Dakota Expansion Drive Outlook

Did Evolution Mining’s (ASX:EVN) Diggers & Dealers Update Clarify Its Long-Term Growth Priorities?

Gevo Q2 Earnings Call Highlights

Gevo reported increased second-quarter revenue and significantly raised its 2026 adjusted EBITDA outlook, driven by strong performance in low-carbon fuels, expected tax credits, and new access to Canada's clean-fuel market. The company is advancing its North Dakota expansion to boost ethanol capacity and is …

Evolus Inc. Earnings Call Signals Confident Growth

Evolus, Inc. reported strong Q2 earnings with double-digit revenue growth and a third consecutive quarter of positive adjusted EBITDA, driven by its toxin franchise and growing international presence. Despite increased operating expenses and tariff uncertainty, the company raised its 2026 revenue guidance and reaffirmed …

Gevo, Inc. (GEVO) Reports Q2 Loss, Beats Revenue Estimates

Gevo, Inc. (GEVO) reported a Q2 loss of $0.01 per share, which beat the Zacks Consensus Estimate of a $0.02 loss, and revenues of $46.5 million, surpassing estimates by 2.23%. Despite underperforming the S&P 500 year-to-date, the company holds a Zacks Rank #2 (Buy) …

Gevo Q2 2026 slides: EBITDA outlook doubles to $60M

Gevo Inc. reported its Q2 2026 earnings, significantly raising its full-year adjusted EBITDA guidance to over $60 million, more than double its previous target. This improved outlook is driven by its carbon business and federal tax credit monetization, with the company expecting substantial positive …

Project write-downs drive steep Q2 loss at Gevo (Nasdaq: GEVO)

Gevo Inc. reported a significant Q2 2026 net loss of $176.9 million, primarily due to non-cash impairment charges of $135.8 million on discontinued projects and a $39.8 million allowance for credit losses. Despite increased revenue, the company underwent a strategic review, prioritizing its ethanol …

Gevo (GEVO) Stock Rises on Q2 2026 Earnings

Gevo, Inc. (GEVO) reported Q2 2026 revenue of $46.5 million, up 7.1% year-over-year, which was in line with analyst expectations. Despite this revenue growth, the company experienced a significant operating loss of $171.7 million and a net loss of $176.9 million, resulting in a …

Gevo (GEVO) insider files to sell equity compensation shares

An insider at Gevo, Inc. (GEVO), Oluwagbemileke Yusuf Agiri, has filed a Form 144 notice to sell up to 18,223 shares of common stock, valued at approximately $28,033.63. These shares originated from restricted stock awards received as equity compensation in August 2023. The filing …

Revolution Medicines, Inc. Stock 12‑Month Price Target Raised to $216.4, Implies 10% Upside

Revolution Medicines, Inc. (RVMD) has seen its average price target raised from $207.16 to $216.4 by 20 analysts, with forecasts ranging from $151 to $263 per share. This updated target suggests a potential 10% upside based on the Aug. 5 closing price. The consensus …

Gevo Exits South Dakota Ethanol and SAF Activities After $176M Charge

Gevo reported its second-quarter 2026 financial results, including a GAAP net loss of $(176.9) million due to a $176 million non-cash impairment charge from exiting South Dakota ethanol and SAF projects. The company raised its full-year 2026 non-GAAP Adjusted EBITDA outlook to over $60 …

Evolent Health Inc (EVH) (Q2 2026) Earnings Call Highlights: Revenue Surges 31% and Guidance ...

Key Points Interested in Evolent Health, Inc? Here are five stocks we like better. Evolent raised its 2026 outlook after Q2 revenue rose 31% sequentially to $653 million and adjusted EBITDA increased 27% to $28 million. Full-year revenue guidance is now $2.6 billion–$2.7 billion, …